Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients With Residual, Relapsed or Refractory Non-Hodgkin Lymphoma

• Status: Recruiting
• Trial end date: 2024-12-15

Summary

This phase Ib trial evaluates the side effects and best dose of choline salicylate given together with a low dose of selinexor in treating patients with diffuse large B cell lymphoma or mantle cell lymphoma that has cancer cells remaining after attempts to remove the cancer have been made (residual), has come back (relapsed) or does not respond to treatment (refractory). Anti-inflammatory drugs, such as choline salicylate lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Selinexor may stop the growth of cancer cells by blocking a protein called CRM1 that is needed for cell growth. help doctors learn more about selinexor and choline salicylate as a treatment for lymphoma. This trial may help doctors learn more about selinexor and choline salicylate as a treatment for lymphoma.

• Phase: Phase 1

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: National Cancer Institute (NCI)
• Treatments: Choline; Salicylates